A Tumor-Activatable DNA Nanoengager That Orchestrates NK Receptor Clustering and Immune Checkpoint Blockage to Enhance Antitumor Cytotoxicity.
Natural killer cell engagers (NKCEs) are promising immunotherapeutic agents for cancer treatment. However, their efficacy against solid tumors is severely limited by immune evasion mechanisms (mediated by the sialic acid-Siglec axis and PD-1/PD-L1 pathway), along with poor pharmacokinetics and off-target effects. Harne...